Key facts
- It has raised $208.0M; the latest was Early Stage VC ($161.0M) in Dec 2024.
- Notable investors include Norwest, B Capital Group, Alexandria Venture Investments, Novo Holdings, Blue Owl Capital — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Nuvig Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuvig Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuvig Therapeutics
Developer of advancing innovative and transformational therapies designed to induce natural mechanisms to restore immune homeostasis and rebalance immune function. The company relies on the therapeutic induction of natural mechanisms of immune homeostasis to modulate immune function, enabling doctors to improve treatment options for patients with chronic inflammatory and autoimmune diseases.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2021
- Employees
- 10
- Website
- nuvigtherapeutics.com/
- Ownership
- Privately Held (backing)
Nuvig Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuvig Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuvig Therapeutics in its N-PORT filings yet. We sweep new filings monthly.